Antiarrhythmic drugs

ApprovedSmall molecule

NNational Institute of Cardiology, Warsaw, Poland

Antiarrhythmic drugs is one of 87 small molecule programs targeting Paroxysmal atrial fibrillation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Paroxysmal Atrial FibrillationActive, not recruiting

Ventricular ArrhythmiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Hypertrophic CardiomyopathyActive, not recruiting

Paroxysmal Atrial FibrillationApproved

Active, not recruiting

Ventricular ArrhythmiaApproved

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

Hypertrophic CardiomyopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Antiarrhythmic drugs

NNational Institute of Cardiology, Warsaw, Poland

Approved

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Calcium

Eli Lilly

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertrophic Cardiomyopathy1 trial

Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy

Completed·NNational Institute of Cardiology, Warsaw, Poland·Phase 3·NCT00821353·90 enrolled

Atrial Fibrillation1 trial

CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation

Terminated·BBiosense Webster EMEA·Phase 4·NCT00227344·129 enrolled

Prospective1 trial

PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN SVT

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03299517·80 enrolled

Paroxysmal atrial fibrillation1 trial

Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation

Completed·MMedtronic Cardiac Ablation Solutions·Phase 4·NCT01803438·220 enrolled

Ventricular arrhythmia1 trial

Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias

Unknown status·OOspedale San Donato·Phase 4·NCT01780311

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Antiarrhythmic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiarrhythmic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiarrhythmic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Cardiology, Warsaw, Poland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Cardiology, Warsaw, Poland

Antiarrhythmic drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertrophic Cardiomyopathy1 trial

Atrial Fibrillation1 trial

Prospective1 trial

Paroxysmal atrial fibrillation1 trial

Ventricular arrhythmia1 trial

References

Drug Info

Quick Facts

Related News